Topical Antiparasitic Drugs in Dermatology: Current Insights, Future Directions

Journal of Skin and Sexually Transmitted Diseases  ·  2026

Nimitha Parambath;

HIGHLIGHT

This review explores the clinical evidence, safety data, therapeutic strategies, and growing challenge of drug resistance of commonly used topical antiparasitic drugs.

RELATED

Papers      Patents     Grants     Venues     Experts    Cite    Share    Save

ABSTRACT

Parasitic skin infestations, including scabies, pediculosis, and demodicosis, remain important clinical problems, particularly in vulnerable populations such as the pediatric population and immunocompromised individuals. Topical antiparasitic drugs, when applied directly to the skin, exert their effect by disrupting the nervous system of these parasites, causing paralysis and death. Because of their targeted action, convenience of use, and favorable safety profile, topical therapies are often considered first-line treatment for many ectoparasitic infestations. Topical antiparasitic drugs such as ivermectin, permethrin, benzyl benzoate, crotamiton, spinosad, and abametapir have an established role in treating ectoparasitic infestations such as scabies and pediculosis. This review explores the clinical evidence, safety data, therapeutic strategies, and growing challenge of drug resistance of commonly used topical antiparasitic drugs.

 Paraphrase     Questionfy     Wikify     Simplify     Summarize